All News #Library
Biotech
Lynk Pharma Announces NDA Acceptance for Zemprocitinib by NMPA
10 Apr 2026 //
PR NEWSWIRE
Lynk sees ph. 3 eczema win as proof of JAK inhibitor`s potential
02 Mar 2026 //
PR NEWSWIRE
Lynk Report Positive Ph3 Data for RA Arthritis Drug Zemprocitinib
12 Jan 2026 //
PR NEWSWIRE
Lynk Pharma, Formation Bio Ink Exclusive Deal For LNK01006
10 Dec 2025 //
PR NEWSWIRE
Lynk Pharma Gets FDA Nod For Allosteric TYK2 Inhibitor LNK01006
02 Dec 2025 //
PR NEWSWIRE
Lynk Pharma Reveals Phase II Results For LNK01004
19 Nov 2025 //
PR NEWSWIRE

Market Place
Sourcing Support